Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail

Summary Background Transition of normal melanocytic cells to malignant melanoma has characteristic features of epithelial to mesenchymal transition. This includes the disruption of the adherens junctions caused by the downregulation of E‐cadherin and the upregulation of N‐cadherin. The cadherins have functional importance in normal skin homeostasis and melanoma development; however, the exact mechanism(s) that regulate the ‘cadherin switch’ are unclear. Objectives To determine the mechanistic role of the PI3K/PTEN pathway in regulating the change in cadherin phenotype during melanoma progression. Methods Using a panel of cell lines representative of the phases of melanoma progression, we determined cellular expressions of the components of the PI3K/PTEN pathway, E‐ and N‐cadherin, and the transcriptional regulators Twist, Snail and Slug with Western blot and immunofluorescence analysis. Transcriptional regulation of E‐cadherin, N‐cadherin, Twist and Snail by the PI3K/PTEN pathway was confirmed using quantitative reverse transcription–polymerase chain reaction. Results Loss or inactivity of PTEN correlated with the switch in cadherin phenotype during melanoma progression. PTEN‐null or inactive cells exhibited high levels of phosphorylated protein kinase B (PKB)/AKT (Serine 473) (PKB‐Ser473‐P), undetectable levels of E‐cadherin and high levels of N‐cadherin. Re‐introduction of PTEN or treatment with the PI3K inhibitor Wortmannin resulted in the re‐expression of E‐cadherin and downregulation of N‐cadherin. This cadherin switch was regulated at the transcriptional level by Twist and Snail which were, in turn, transcriptionally regulated by the PI3K pathway. Although E‐cadherin was re‐expressed, it failed to localize to the plasma membrane. Conclusions The PI3K/PTEN pathway transcriptionally regulates the ‘cadherin switch’ via transcriptional regulation of Twist and Snail but does not regulate the localization of E‐cadherin to the plasma membrane.